Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach.
Coley’s toxins
cancer
economic burden of cancer
evaluation of the response
historical overview
immunotherapy
toxicity of immunotherapy
Journal
Integrative cancer therapies
ISSN: 1552-695X
Titre abrégé: Integr Cancer Ther
Pays: United States
ID NLM: 101128834
Informations de publication
Date de publication:
Historique:
entrez:
23
2
2019
pubmed:
23
2
2019
medline:
18
12
2019
Statut:
ppublish
Résumé
Oncology is currently a sector of medical science with accelerated progress due to rapid technological development, the advancement in molecular biology, and the invention of many innovative therapies. Immunotherapy partially accounts for this advance, since it is increasingly playing an important role in the treatment of cancer patients, bringing on a sense of hope and optimism through a series of clinical studies and cases with spectacular results. Immunotherapy, after the initial successes it experienced in the early 20th century, was forgotten after chemotherapy and radiotherapy prevailed and developed slowly in the background. Today, it is the new hope for cancer treatment, despite the unorthodox path it has followed. In this article, we study the course and key points of the discovery of immune-oncology from the oncologist's point of view. We also record the questions that have been posed about immunotherapy that sometimes lead to confusion or stalemate.
Identifiants
pubmed: 30791740
doi: 10.1177/1534735419827090
pmc: PMC7242802
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1534735419827090Références
Cancer Immunol Immunother. 2006 Apr;55(4):451-8
pubmed: 16034562
J Clin Oncol. 1999 Jul;17(7):2105-16
pubmed: 10561265
Oncologist. 2001;6(1):34-55
pubmed: 11161227
Lancet Oncol. 2016 Nov;17(11):1497-1508
pubmed: 27745820
Nature. 1987 Jul 16-22;328(6127):267-70
pubmed: 3496540
Scientifica (Cairo). 2014;2014:970315
pubmed: 24741445
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6681-8
pubmed: 17982122
Prog Exp Tumor Res. 1970;13:1-27
pubmed: 4921480
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Lancet Oncol. 2016 Jun;17(6):717-726
pubmed: 27157491
Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2006-14
pubmed: 21980008
Cancer Treat Res. 2018;175:127-137
pubmed: 30168120
Immunity. 1995 Nov;3(5):541-7
pubmed: 7584144
Aging (Albany NY). 2015 Aug;7(8):521-2
pubmed: 26298620
Hum Vaccin Immunother. 2014;10(11):3415-24
pubmed: 25483656
J Urol. 2002 Feb;167(2 Pt 2):891-3; discussion 893-5
pubmed: 11905917
Lancet. 2018 Feb 24;391(10122):748-757
pubmed: 29268948
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
N Engl J Med. 2004 Jul 22;351(4):317-9
pubmed: 15269308
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Lancet Oncol. 2017 May;18(5):623-630
pubmed: 28291584
Invest New Drugs. 2018 Aug;36(4):638-646
pubmed: 29159766
Ecancermedicalscience. 2015 Dec 03;9:604
pubmed: 26715941
Adv Exp Med Biol. 1990;267:483-500
pubmed: 2088067
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
J Clin Oncol. 2015 Jun 10;33(17):1889-94
pubmed: 25667295
J Exp Med. 2000 Feb 21;191(4):661-8
pubmed: 10684858
EMBO J. 1992 Nov;11(11):3887-95
pubmed: 1396582
Clin Cancer Res. 2015 Feb 15;21(4):749-55
pubmed: 25538262
Lancet Oncol. 2015 May;16(5):522-30
pubmed: 25840693
Scientifica (Cairo). 2013;2013:857519
pubmed: 24278787
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Oncotarget. 2017 Oct 6;8(53):91779-91794
pubmed: 29207684
Science. 1995 Nov 10;270(5238):985-8
pubmed: 7481803
Front Immunol. 2016 Dec 12;7:550
pubmed: 28018338
Curr Opin Immunol. 2014 Apr;27:16-25
pubmed: 24531241
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Allergy Asthma Clin Immunol. 2013 Aug 15;9(1):30
pubmed: 23947590
Curr Treat Options Neurol. 2018 Apr 18;20(5):14
pubmed: 29666934
Nat Rev Urol. 2018 Mar;15(3):137
pubmed: 29297891
N Engl J Med. 2016 Nov 10;375(19):1845-1855
pubmed: 27717298
Immunology. 2007 May;121(1):1-14
pubmed: 17386080
Cancer Res. 1953 Dec;13(12):835-7
pubmed: 13116120
Oncologist. 2017 Aug;22(8):951-962
pubmed: 28526721
N Engl J Med. 2015 May 21;372(21):2006-17
pubmed: 25891304
J Clin Oncol. 2016 May 1;34(13):1510-7
pubmed: 26951310
Postgrad Med J. 2003 Dec;79(938):672-80
pubmed: 14707241
Clin Cancer Res. 2017 Oct 1;23(19):5666-5670
pubmed: 28235882
Ther Adv Med Oncol. 2015 Mar;7(2):97-106
pubmed: 25755682
Iowa Orthop J. 2006;26:154-8
pubmed: 16789469
Expert Rev Anticancer Ther. 2017 Jun;17(6):537-543
pubmed: 28425820
Ann Oncol. 2018 Oct 1;29(10):2052-2060
pubmed: 30052729
Cancer Res. 1998 Aug 15;58(16):3491-4
pubmed: 9721846
Chin J Cancer. 2014 Sep;33(9):445-57
pubmed: 25189717
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
JAMA Oncol. 2017 Dec 1;3(12):1628-1629
pubmed: 28983562
N Engl J Med. 2015 Nov 12;373(20):1979
pubmed: 26559582
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
Med Hypotheses. 2003 Apr;60(4):603-6
pubmed: 12615532
Nat Med. 1999 Dec;5(12):1365-9
pubmed: 10581077
Cancer. 1993 Nov 15;72(10):2993-3001
pubmed: 8221567
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
Annu Rev Immunol. 2004;22:329-60
pubmed: 15032581
Manag Care. 2013 Oct;22(10):54-6
pubmed: 24350383
Lancet. 2018 Jul 14;392(10142):123-133
pubmed: 29880231
Transl Lung Cancer Res. 2015 Oct;4(5):560-75
pubmed: 26629425
N Engl J Med. 2009 Feb 5;360(6):626-33
pubmed: 19176475
Pharmacol Ther. 1994;64(3):529-64
pubmed: 7724661